Clovis +8.6% AH, Dendredon +1.9% on positive ASCO data

|By:, SA News Editor

Clovis (CLVS) and Dendreon (DNDN) have both presented abstracts ahead of the American Society of Clinical Oncology's (ASCO) May 30-June 3 annual meeting.

Clovis is presenting five abstracts related  to Phase 1/2 studies for three of its compounds, including CO-1686 (aims to treat non-small cell lung cancer).

Dendreon is presenting two abstracts related to a phase 2 study and Proceed registry data for its Provenge prostate cancer immunotherapy.

ASCO abstract search